WO1997013503A9 - Synthese de nanoparticules medicamenteuses par sechage par pulverisation - Google Patents
Synthese de nanoparticules medicamenteuses par sechage par pulverisationInfo
- Publication number
- WO1997013503A9 WO1997013503A9 PCT/US1996/016417 US9616417W WO9713503A9 WO 1997013503 A9 WO1997013503 A9 WO 1997013503A9 US 9616417 W US9616417 W US 9616417W WO 9713503 A9 WO9713503 A9 WO 9713503A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- nanoparticles
- ethyl
- diacetamido
- triiodobenzoate
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 124
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 238000001694 spray drying Methods 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title description 40
- 230000015572 biosynthetic process Effects 0.000 title description 10
- 238000003786 synthesis reaction Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 75
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 239000011159 matrix material Substances 0.000 claims abstract description 58
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 51
- 239000002131 composite material Substances 0.000 claims abstract description 33
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 12
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 11
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 239000000575 pesticide Substances 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 105
- OBISGMNJKBVZBT-UHFFFAOYSA-N ethyl 3,5-diacetamido-2,4,6-triiodobenzoate Chemical group CCOC(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I OBISGMNJKBVZBT-UHFFFAOYSA-N 0.000 claims description 63
- 239000002114 nanocomposite Substances 0.000 claims description 47
- -1 ?-D-lactose Chemical compound 0.000 claims description 39
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 29
- 229960002009 naproxen Drugs 0.000 claims description 29
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 29
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 26
- 235000000346 sugar Nutrition 0.000 claims description 23
- 229930006000 Sucrose Natural products 0.000 claims description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 17
- 239000005720 sucrose Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N L-sorbitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 235000002639 sodium chloride Nutrition 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 229920002554 vinyl polymer Polymers 0.000 claims description 8
- HBDJFVFTHLOSDW-XBLONOLSSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;hydrate Chemical compound O.O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O HBDJFVFTHLOSDW-XBLONOLSSA-N 0.000 claims description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 4
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- 108010055615 Zein Proteins 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 229940078456 calcium stearate Drugs 0.000 claims description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- UAMZXLIURMNTHD-UHFFFAOYSA-N dialuminum;magnesium;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Mg+2].[Al+3].[Al+3] UAMZXLIURMNTHD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229960001419 fenoprofen Drugs 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 4
- 229960001680 ibuprofen Drugs 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- 229960002900 methylcellulose Drugs 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- 244000106483 Anogeissus latifolia Species 0.000 claims description 3
- 235000011514 Anogeissus latifolia Nutrition 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 240000008886 Ceratonia siliqua Species 0.000 claims description 3
- 244000303965 Cyamopsis psoralioides Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 239000001922 Gum ghatti Substances 0.000 claims description 3
- 229920000569 Gum karaya Polymers 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 3
- 235000015125 Sterculia urens Nutrition 0.000 claims description 3
- 240000001058 Sterculia urens Species 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229940081735 acetylcellulose Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000001961 anticonvulsive agent Substances 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 229940125708 antidiabetic agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 3
- 229940092690 barium sulfate Drugs 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229960003563 calcium carbonate Drugs 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 229960002227 clindamycin Drugs 0.000 claims description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 3
- 239000008139 complexing agent Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229960004667 ethyl cellulose Drugs 0.000 claims description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 125000005908 glyceryl ester group Chemical group 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 235000019314 gum ghatti Nutrition 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 239000000231 karaya gum Substances 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 230000000873 masking effect Effects 0.000 claims description 3
- QFVDKARCPMTZCS-UHFFFAOYSA-N methylrosaniline Chemical compound C1=CC(N(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 QFVDKARCPMTZCS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003158 myorelaxant agent Substances 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 150000002960 penicillins Chemical class 0.000 claims description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 230000001846 repelling effect Effects 0.000 claims description 3
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 229960003885 sodium benzoate Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 229960004025 sodium salicylate Drugs 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
- 239000012177 spermaceti Substances 0.000 claims description 3
- 229940084106 spermaceti Drugs 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims 1
- 239000001904 Arabinogalactan Substances 0.000 claims 1
- 229920000189 Arabinogalactan Polymers 0.000 claims 1
- 235000019312 arabinogalactan Nutrition 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 239000000975 dye Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 40
- 239000007921 spray Substances 0.000 description 32
- 238000009472 formulation Methods 0.000 description 23
- 239000003607 modifier Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000008569 process Effects 0.000 description 21
- 239000004094 surface-active agent Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000009826 distribution Methods 0.000 description 15
- 238000001035 drying Methods 0.000 description 15
- 239000006185 dispersion Substances 0.000 description 13
- 239000003381 stabilizer Substances 0.000 description 13
- 239000013078 crystal Substances 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002441 X-ray diffraction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920002689 polyvinyl acetate Polymers 0.000 description 8
- 239000011118 polyvinyl acetate Substances 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- PITRRWWILGYENJ-UHFFFAOYSA-N 2-[2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCO)C=C1 PITRRWWILGYENJ-UHFFFAOYSA-N 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 7
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000002518 antifoaming agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960001031 glucose Drugs 0.000 description 5
- 229920001993 poloxamer 188 Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920002359 Tetronic® Polymers 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940077731 carbohydrate nutrients Drugs 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229940024545 aluminum hydroxide Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000011246 composite particle Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000006911 nucleation Effects 0.000 description 3
- 238000003921 particle size analysis Methods 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CKIPPJHUIHDREQ-TUJAQXOJSA-N Arabino-galactose Chemical compound O[C@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1 CKIPPJHUIHDREQ-TUJAQXOJSA-N 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 244000180278 Copernicia prunifera Species 0.000 description 2
- 235000010919 Copernicia prunifera Nutrition 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920000847 nonoxynol Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000005549 size reduction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- CGVLVOOFCGWBCS-UHFFFAOYSA-N 2-(hydroxymethyl)-6-octylsulfanyloxane-3,4,5-triol Chemical compound CCCCCCCCSC1OC(CO)C(O)C(O)C1O CGVLVOOFCGWBCS-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical class CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- NIDYWHLDTIVRJT-UJPOAAIJSA-N heptyl-β-d-glucopyranoside Chemical compound CCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NIDYWHLDTIVRJT-UJPOAAIJSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- RTVVXRKGQRRXFJ-UHFFFAOYSA-N sodium;2-sulfobutanedioic acid Chemical compound [Na].OC(=O)CC(C(O)=O)S(O)(=O)=O RTVVXRKGQRRXFJ-UHFFFAOYSA-N 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 229910001233 yttria-stabilized zirconia Inorganic materials 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Definitions
- the present invention relates to the field of drug manufacture, and, in particular, to the synthesis of therapeutic, diagnostic, analgesic, and antiinflammatory compositions having a median particle size less than about 5000 nm.
- a drug When a drug is administered into a body, it typically must cross a series of membranes before reaching the site of action where its activity can have a desired effect.
- oral administration of a drug having a systemic site or sites of action will provide limited or no relief unless the drug crosses the gut wall.
- the ability of a drug to cross the gut wall can be controlled by the way in which the active substance is formulated.
- the formulation can also provide control as to the site of action of a given drug, and the rate at which the drug is available at that site. For instance, the same amount of drug could have a different effect when administered as an oral solution than when administered as a tablet because of the differences in the rate at which the drug is absorbed from the gut in the two cases.
- nanoparticles include the fact that drugs administered as nanoparticles have increased surface areas relative to larger sized drug particles, which correlates with increased absorption and utilization of the drug. Prescot et al., Clin. Pharm. Therap. , 1 1 , 496.
- naproxen the dextrorotatory isomer of 6-methoxy- ⁇ r-nr.ethyl-2-naphthalene acetic acid.
- Naproxen has been shown to possess analgesic and anti-inflammatory activity in the treatment of rheumatoid arthritis, for example, for which naproxen nanoparticles can be more effective than aspirin, indomethacin, ibuprofen, and fenoprofen. These nanoparticles are better tolerated, thus enabling more patients to continue with the treatment.
- nanoparticles are agents for X-ray diagnostic medical imaging.
- organic nanoparticles such as iodine-substituted ethyl benzoates, iothalamates, metrizoates and iodipamides, have been identified for X-ray contrast imaging because of their low solubility in aqueous media (less than about 10 mg/mL), and not being radioactive.
- Such nanoparticles provide effective imaging of tissue or fluid sites of the human body for up to 2 h and longer when administered intravenously as aqueous colloidal dispersions for the imaging of blood pool, liver, kidney, bone marrow, lymph nodes and spleen, for example. See EP 0 498 482 A2 and US Patents 5, 1 45,684; 5,298,262; 5,233,995; and 5,302,401 .
- a novel spray drying method has been developed to synthesize drug nanoparticles having median sizes of less than about 5000 nm. This method involves spray drying different concentrations of the drug dissolved in dimethyl sulfoxide (DMSO),
- 1 -methyl-2-pyrroIidinone (1 2 MPO), ethanol, or water, with or without surfactants, sugars including sucrose, D( + Hactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol, and stabilizers.
- this invention relates to how the precursor chemistry can be manipulated that leads to the formation of drug particles as small as less than about 40 nm, and the versatility of the method in mass producing nanocomposite powders, which can be rehydrated in the presence of suitable surfactants including a polaxamer, such as PluronicTM F-68, a polyoxyethylene alcohol, such as Brij ® 30, a nonoxynol, such as igepal CO-520 ® , and TetronicTM 908, and polymeric stabilizers including polyvinyl atcohol-polyvinyl acetate copolymers to form pharmaceutically acceptable drug nanoparticle formulations.
- suitable surfactants including a polaxamer, such as PluronicTM F-68, a polyoxyethylene alcohol, such as Brij ® 30, a nonoxynol, such as igepal CO-520 ® , and TetronicTM 908, and polymeric stabilizers including polyvinyl atcohol-polyvinyl acetate cop
- the present invention is directed to a method for synthesizing nanoparticles comprising (a) combining an agent and a matrix material to form a composite mixture; and (b) spray drying the composite mixture, forming a nanocomposite.
- the matrix material is at least 10% of the nanocomposite.
- the agent can be a diagnostic, therapeutic, cosmetic, dye, photographic, food, pesticide agent, or metal catalyst.
- the diagnostic agent is any suitable agent used to diagnose a disease or condition, such as, but not limited to, ethyl 3,5-diacetamido-2,4,6-triiodobenzoate.
- the therapeutic agent is any suitable agent for the treatment of a disease or condition selected from the group consisting of, but not limited to, an antiinflammatory agent, an antibiotic agent, an antifungal agent, an antiviral agent, an antineoplastic agent, an immunosuppressive agent, an immunostimulatory agent, an odor masking agent, an insect repelling agent, an anesthetic agent, an antiseptic agent, an antioxidant, an antihistamine, an antidiabetic agent, an antiepileptic agent, a muscle relaxant, a stimulant, an antiallergic agent, a liposaccharide complexing agent, a vitamin, a hormone, an anticancer agent, and a cough suppresant.
- a preferred antiinflammatory agent is naproxen.
- the nanoparticles of the present invention are formulated as a colloidal suspension, capsule, tablet, or powder.
- the ratio of agent to matrix material used in the context of the present invention is from about 10: 1 to about less than 1 : 100, as judged from analysis of the nanocomposite; and the agent and matrix material are combined in the presence of organic and aqueous solvents.
- the present method further comprises atomizing the composite mixture, which preferably forms droplets of from about 1 ⁇ m to about 100 ⁇ m, more preferably from about 1 ⁇ m to about 75 ⁇ m, and yet more preferably from about 1 ⁇ m to about 50 ⁇ m.
- the nanoparticles produced in the context of the present invention have a median size that is less than about 5000 nm. Preferably, the nanoparticles have a median size of less than about
- the nanoparticles of the present invention are produced amidst a matrix, wherein the matrix is formed from a matrix material comprising a carbohydrate, a protein, an inorganic salt, a resin, or a Iipid.
- the carbohydrate is a sugar selected from the group consisting of sucrose, glucose, fructose, mannose, maltose,
- the carbohydrate can also be selected from the group consisting of cellulose acetate, cellulose acetate phthalate, carboxymethyl cellulose, ethyl cellulose, carboxymethyl cellulose calcium or sodium, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose phthalate, noncrystalline cellulose, starch, and arabinogalactose.
- the carbohydrate is a natural polysaccharide selected from the group consisting of gum arabic (acacia), gum ghatti, karaya, tragacanth, locust bean, guar and xanthan gum.
- the inorganic salt is selected from the group consisting of sodium chloride, potassium chloride, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, sodium benzoate, calcium stearate, calcium carbonate, barium sulfate, sodium salicylate, sulfathiazole sodium salt, alumina salts, magnesia salts, alumina-magnesia salts, formed from inter alia aluminum hydroxide, and the like.
- the protein is collagen, gelatin, or zein.
- the alumina salts, magnesia salts, alumina-magnesia salts, formed from inter alia aluminum hydroxide, and the like forms a gel.
- the resin is selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyarylic acid, polyethylene, polymethacrylate, polyamide (nylon), poly [ethylene-vinyl acetate], and shellac;
- the Iipid is selected from the group consisting of synthetic and natural phospholipids, glyceryl esters, paraffin, carnauba, spermaceti, beeswax, steric acid, stearyl alcohol and glycerol stearates;
- the protein is gelatin, zein, or collagen.
- the matrix further comprises a stabilizer, a surface modifier, a disintegrating agent, or a lubricating, which may include compounds listed above.
- the nanoparticle comprises ethyl 3,5-diacetamido-2,4,6-triiodobenzoate as the diagnostic agent and the nanoparticles have a median size of from about 1 60 nm to about 280 nm.
- the nanoparticle comprises an antiinflammatory agent such as aspirin, naproxen, indomethacin, ibuprofen, fenoprofen or acetaminophen or an antibiotic agent selected from the group of penicillins, tetracyclins, aminiglycoside antibiotics, and clindamycin.
- an antiinflammatory agent such as aspirin, naproxen, indomethacin, ibuprofen, fenoprofen or acetaminophen
- an antibiotic agent selected from the group of penicillins, tetracyclins, aminiglycoside antibiotics, and clindamycin.
- a preferred embodiment of the present invention provides a method for synthesizing nanoparticles comprising naproxen as the antiinflammatory agent, sucrose as the matrix, poiyvinyl alcohol-polyvinyl acetate copolymers, PluronicTM F-68, or TetronicTM 908, and the nanoparticles have a median particle size of from about
- Another preferred embodiment of the present invention is a pharmaceutical formulation comprising a nanoparticle synthesized by a method comprising (a) combining an agent and a matrix; and (b) spray drying the combined agent and matrix; and a pharmaceutical carrier.
- a method comprising (a) combining an agent and a matrix; and (b) spray drying the combined agent and matrix; and a pharmaceutical carrier.
- Fig. 2 is a diagram relating to the stages of the spray drying process.
- Fig. 3 is a graph that depicts the results of an energy dispersive analysis by X-ray, demonstrating the presence of the iodine atoms of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP- 1 ) throughout the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate-containing nanoparticles.
- CMP- 1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
- Fig. 4 is a graph depicting median particle size as a function of the initial concentration of ethyl 3,5-diacetamido-2,4,6- triiodobenzoate (CMP-1 ).
- Fig. 5 is a graph depicting median particle size as a function of the initial concentration of PluronicTM F-68.
- Fig. 6 is a graph depicting the change in particle size distribution of spray dried ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP-1 ) as a function of sonication time.
- Fig. 7 is a graph depicting x-ray diffraction results of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP-1 ) nanoparticles comparing conventionally precipitated powders and spray-dried powders.
- CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
- Fig. 8 is a graph depicting x-ray diffraction results of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate (CMP-1 ) nanoparticles generated in the presence or absence of PluronicTM F-68.
- CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
- Fig. 9 is a graph depicting x-ray diffraction results of ethyl cellulose powder and spray dried naproxen-ethyl cellulose nanocomposite. DESCRIPTION OF THE INVENTION
- a nanoparticle is formed substantially of an active agent ("the agent”) and is between about 1 0 nm and about 5000 nm in size.
- a nanoparticle substantially formed of the agent is a nanoparticle that is at least about 80% by weight composed of the agent, more preferably at least about 90%, yet more preferably at least about 95%, and most preferably at least about 99%; the remainder of the content of a nanoparticle is composed of surface modifiers, surfactants, and other matrix material discussed hereinbelow. (Note that all percentages recited in this specification with respect to proportional content are proportions by weight, unless otherwise labeled) .
- the nanoparticles synthesized in the context of the present invention are preferably uniform in spatial distribution with respect to the matrix, as seen by electron microscopy. For example, for nanoparticles having a size between about 10 nm and about 100 nm, such nanoparticles are found within about 200 nm to about 500 nm of each other; for nanoparticles having a size between about 200 nm and about 400 nm, such nanoparticles are found within about 400 nm to about 1000 nm of each other; and for nanoparticles having a size between about 1000 nm and about 5000 nm, such nanoparticles are found within about 2000 nm to about 3000 nm of each other.
- the nanoparticles synthesized in the context of the present invention preferably are uniform in distribution of size for a given set of process parameters used to generate the nanoparticles, which process parameters are further discussed hereinbelow.
- process parameters are further discussed hereinbelow.
- at least more than about 10% of the nanoparticles can be synthesized having a given size, more preferably, at least more than about 50% of the nanoparticles can be synthesized having a given size, and yet more preferably, at least more than about 90% of the nanoparticles can be synthesized having a given size.
- nanoparticles are synthesized dispersed within a matrix within or by which the nanoparticles are formed.
- Any material included in a nanocomposite that is not a nanoparticle is considered herein to be part of the matrix, and the matrix can be a porous or a dense structure.
- a suitable matrix material is any chemical, compound, or structure that is a solid at room temperature (i.e., about 25 * C), including but not limited to the examples set forth hereinbelow.
- the size of a nanoparticle is less than about 5000 nm and at least about 10 nm, preferably less than about 1 000 nm, more preferably less than about 400 nm, and most preferably less than about 250 nm.
- the material of the matrix (“the matrix material”) is in a solid or solute phase, or the dried product thereof, and forms the aforementioned matrix.
- the combination of the agent and the matrix material is referred to herein as the "composite mixture,” from which, upon spray drying, is formed the aforementioned nanocomposite.
- the composite mixture particularly in the presence of a solvent, which, as further discussed below, can be organic or aqueous or both, forms a solution, which is prefered, or a suspension.
- the particulate matter within the mixture may require further processing to allow formation of nanoparticles of the present invention.
- the agent is present as particles that are greater or similar to the size of nanoparticles desired, then the present process includes a step to reduce the size of the agent.
- the matrix material may require a size reduction to assure the desired size of nanocomposite, and of the resultant nanoparticles.
- Such further processing involves any suitable process for size reduction of such particulate matter, such as, but not limited to, sonication, microfluidization, or milling, or a combination thereof, using methods known to the art.
- the composite mixture is preferably a solution, although in an alternative embodiment, the composite mixture is a suspension, wherein the suspended particulate matter can be agent or matrix material, and preferably is matrix material only.
- the composite mixture comprises a sufficient concentration of matrix material that, upon spray drying, a matrix is believed to be formed by the so- treated matrix material.
- the dissolved agent included in the composite mixture is believed to be contained within pores or upon the surface of the matrix, by which the agent forms nanoparticles in the spray drying process.
- Matrix material can constitute over 99% of the nanocomposite.
- the matrix material comprises about 60% of the nanocomposite.
- the matrix material comprises about a majority of the nanocomposite, more preferably the matrix material comprises about 40% of the nanocomposite, even more preferably the matrix material comprises about 25% of the nanocomposite, yet more preferably the matrix material comprises about 1 5% of the nanocomposite, and most preferably, the matrix material comprises about 10% of the nanocomposite.
- solvent included with the composite mixture is removed by evaporation, thereby increasing the concentration and viscosity of the matrix material, which in turn restricts the mobility (via diffusion, for example) of the agent while in solution.
- the matrix is believed to be formed by the matrix material in this process and is believed to confine the distribution of the agent included in the composite mixture within the surface structure of the matrix.
- the agent is believed to supersaturate and thereafter precipitate as a consequence of inherent properties of the matrix material, such as viscosity, molecular weight, porosity, pore size, and the like.
- Viscosity of the matrix can range from about 100 cp to about 100,000 cp, preferably from about 1 00 to about 5,000 cp, and more preferably from about 100 cp to about 1 ,000 cp.
- Preferred matrices have a porous structure, which porosity is preferably from about 10% to about 90%, more preferably from about 50% to about 90%.
- Preferred pore size of the matrix material or resultant matrix is from about 5 nm to about 500 nm, more preferably from about 10 nm to about 100 nm.
- Spray drying is a process of converting a liquid into a powder by spraying the liquid into a hot drying gaseous medium. This process constitutes: (i) generation of liquid aerosol droplets,
- the particle morphology also depends on the drying conditions.
- a particle formed by spray drying of solution is composed of many crystallites.
- the nature of the solvent and the addition of surfactant to the solution can affect the nucleation and growth processes, and hence the crystallite size.
- an instantaneous nucleation has to be induced throughout the solution, and agglomeration must be avoided.
- the residence time of the composite mixture in the spray dryer is no more than about 25 seconds, more preferably no more than about 1 5 seconds, and most preferably no more than about 1 0 seconds.
- Ostwald ripening must be prevented.
- hollow particles comprising single crystals or solid single crystals, hollow crust, crystal platelets, or needle-shaped crystal
- hollow particles comprising single crystals or solid single crystals, hollow crust, crystal platelets, or needle-shaped crystal
- suitable alterations to the spray drying process with respect to temperature, humidity, solvent evaporation rate, solute solubility, interfacial energy, particle mass and crystal growth rates.
- evaporation and crystal growth rates and solubility solid single crystal particles or particles consisting of an ensemble of small crystals can be obtained.
- the particle size and morphology can be varied by altering the initial concentration of the solution, surfactant concentration, and otherwise altering the composite mixture.
- Spray drying has been employed in the pharmaceutical industry for: (i) drying a variety of heat sensitive biological materials, including plasma, proteins, enzymes, sera, microorganisms and yeasts; (ii) improving the solubility of water-soluble substances; (iii) increasing the flow properties of free-flowing granules for tablet preparation; and (iv) improving the dispersibility of methylcellulose.
- heat sensitive biological materials including plasma, proteins, enzymes, sera, microorganisms and yeasts
- improving the solubility of water-soluble substances including plasma, proteins, enzymes, sera, microorganisms and yeasts
- improving the solubility of water-soluble substances including water-soluble substances; (iii) increasing the flow properties of free-flowing granules for tablet preparation; and (iv) improving the dispersibility of methylcellulose.
- prior uses of spray drying have not provided nanoparticles of uniform median sizes, such as those of less than about 5000 nm, more preferably of less than about 1 000 nm, yet more preferably of less than about 400 nm, and most preferably of less than about 250 nm; and greater than at least about 10 nm.
- Nanoparticles of the present invention are preferably prepared in the presence of matrix material that forms a solid at room temperature (about 25 ° C), such as a carbohydrate, including a sugar selected from the group consisting of sucrose, D( + )-lactose monohydrate, ?-D-lactose, L(-)-sorbose, glucose, fructose, mannose, maltose, sorbitol, and D-mannitol.
- matrix material that forms a solid at room temperature (about 25 ° C)
- Nanoparticles are also preferably prepared in the presence of stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers; and in the presence of surfactants, including but not limited to a polaxamer, such as PluronicTM F-68 or F-108 (manufactured by BASF- Wyandotte), which is a block copolymer of ethylene oxide and propylene oxide, a polyoxyethylene alcohol, such as Brij ® 30 (manufactured by ICI), a nonoxynol, such as Igepal CO-520 ® (manufactured by GAF), and TetronicTM 908.
- stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers
- surfactants including but not limited to a polaxamer, such as PluronicTM F-68 or F-108 (manufactured by BASF- Wyandotte), which is a block copolymer of ethylene oxide and propylene oxide
- the powder produced by spray drying can be rehydrated to form pharmaceutically acceptable drug nanoparticle formulations with particle size of less than about 5000 nm, preferably less than about 1000 nm, more preferably less than about 400 nm, and most preferably less than about 250 nm.
- a surface modifier adsorbed on the surface of the nanoparticle is preferably included in the nanoparticle production as well.
- the present invention is also related to spray drying solutions with different process parameters, including suitable matrix material/agent concentration in the composite mixture, drying temperature, residence time of the composite mixture in the spray dryer, solvent and the presence of surfactant to produce the preferred drug nanoparticles.
- concentration of the matrix material/agent component of the composite mixture can be any concentration to the extent that the composite mixture remains atomizable and the matrix forms.
- the composite mixture must be pumpable, which is consistent with the composite mixture having a viscosity of no more than about 300 cp, more preferably no more than about 200 cp, yet more preferably no more than 100 cp.
- drying temperatures are those that provide for adequate drying such that the nanoparticles are formed, and of a temperature range that the agent does not become inactivated or substantially inactivated.
- drying temperatures are less than about 275 ° C, preferably about 200 ⁇ C, more preferably about 1 50° C.
- the drying temperatures are less than about 1 50 ° C, preferably about 125 * C, or 90 " C, or 75 " C, or 50 ° C.
- a spray drying process incorporates a combination of different temperatures as herein discussed, or a gradient of such temperatures, or any combination thereof.
- Suitable residence times are those that are sufficiently short so as to prevent phase separation of the components of the composite mixture in the spray dryer.
- suitable residence times are less than about 25 seconds, more preferably less than about 1 5 seconds, yet more preferably less than about 10 seconds.
- Preferred surface modifiers can be low molecular weight polymers (molecular weight less than about 2000) including nonionic and ionic surfactants; natural products and various polymers, and high molecular weight (molecular weight less than about 20,000 to about 40,000) steric stabilizers including polyvinyl alcohol-polyvinyl acetate copolymers, for example.
- the surface modifiers preferably do not chemically react with the agent or itself.
- Representative nanocomposite host matrices for the drug include without limitation carbohydrates including sugars, e.g., glucose, fructose, lactose, mannitol, sucrose, maltose, trehalose, sorbitol, mannitol, and mannose; celluloses, e.g., cellulose acetate, cellulose acetate phthalate, carboxymethyl cellulose, ethyl cellulose, carboxymethyl cellulose calcium or sodium, carboxymethyl cellulose sodium, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propymethyllcellulose phthalate and noncrystalline cellulose; and other suitable carbohydrates, such as starch and arabinogalactose; suitable proteins, e.g., collagens, zein, and gelatin; inorganic salts, e.g., sodium chloride, potassium chloride, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, sodium
- the matrix material can be in the form of a gel, as in, for example, alumina-magnesia gels, aluminum hydroxide gel and magnesia gel.
- Resins useful in the context of the present invention are high polymers of natural or synthetic origin, including those set forth above.
- Suitable lipids useful in the context of the present invention form porous solid structures at room temperature (about 25 ° C), more preferably at about 50 " C, yet more preferably at about l OO ' C, and even more preferably at about 1 50 ° C.
- Nanocomposite host matrices particularly useful in the present invention are water-soluble sugars such as sucrose, D( + )-lactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol; stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers; and surfactants such as PluronicTM F-68, Brij ® 30, Igepal CO-520 ® and TetronicTM 908.
- the amount of a sugar in the nanocomposite particles can vary from about 10 to 90%, preferably
- Examples of some representative surface modifiers are gelatin, casein, phospholipids, stearic acid, gum acacia, cholesterol, benzalkonium chloride, calcium stearate, magnesium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl esters, e.g., macrogol esters such as cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, the commercially available TweensTM, such as Tween 80 having formula weight 1309.68 (purchased from Aldrich Chemical Co., Inc., Catalog # 27,436-4) polyethylene glycols, polyoxyethylene stearates, colloidal silicon dioxide, phosphate, sodium dodecyl sulfate, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propymethyll
- surface modifiers include polyvinylpyrrolidinone, tyloxapol, polaxamers such as PluronicTM F-68 and F-108 (manufactured by BASF-Wyandotte), which are block copolymers of ethylene oxide and propylene oxide, and polyoxamines such as TetronicTM 908 (manufactured by BASF), which is a tetrafunctional block copolymer derived from subsequent addition of propylene oxide and ethylene oxide to ethylenediamine; dextran, lecithin, dialkyl esters of sodium sulfosuccinic acid, such as Aerosol OTTM (manufactured by American Cyanimid), which is a dioctyl ester of sodium sulfosuccinic acid, i.e., do
- a polysorbate such as TweenTM (manufatured by ICI Specialty Chemicals), and polyethylene glycols, such as CarbowaxTM 3350 and 934 (manufactured by Union Carbide) .
- Surface modifiers which have been particularly useful include Tetronic 908, the TweensTM, and Pluronic F-68.
- Other useful surface modifiers include: decanyl-N-methylglucamide, n-decyl 5-D-glucopyranoside, n-decyl ?-D-maltopyranoside, n-dodecyl ?-D-glucopyranoside, n-dodecyl /3-D-maltoside, heptanoyl-N-methylglucomide, n-heptyl ⁇ -D- glucopyranoside, n-heptyl ?-D-thioglucoside, n-hexyl ?-D-glucopyranoside, nananoyl-N-methylglucamide, n-nonyl jff-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl ⁇ -D-giucopyranoside, and n-octyl ?-D-thioglucopyranoside.
- Surface modifiers useful in the present invention are PluronicTM F-68 (a nonionic solid copolymer of ethylene oxide and propylene oxide), and TetronicTM 908 (a solid nonionic tetrafunctional block copolymer derived from subsequent addition of propylene oxide and ethylene oxide to ethylenediamine).
- the relative amount of therapeutic or diagnostic agent and surface modifier can vary widely and the optimal amount of surface modifier can depend, for example, upon the therapeutic or diagnostic agent and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the hydrophilic-lipophilic balance (HLB) of the stabilizer, the surface tension of water solutions of the stabilizer and the melting point of the stabilizer.
- HLB hydrophilic-lipophilic balance
- a method for the preparation of a nanoparticle composition includes dissolving a therapeutic or diagnostic agent, optionally a nanocomposite host material, and a surface modifier in a suitable solvent.
- the resulting solution is atomized into droplets and these droplets are converted into solid particles in a horizontal spray dryer. If a surface modifier or polymeric stabilizer is not present in the as-sprayed particles, it can be admixed thereafter.
- the liquid medium especially water, can serve as the pharmaceutically acceptable carrier.
- the method preferably is carried out under aseptic conditions.
- the particle size corresponds to a number median particle size as measured by the conventional particle size measuring techniques, such as laser light scattering methods.
- a median particle size means that at least about 50% of the particles have a number average particle size of the specified size when measured by the above-mentioned techniques, which defines the term "d 50 . ". Accordingly, a "median particle size of less than about 5000 nm” means that at least 50% of the particles have a number average particle size of less than about 5000 nm.
- the median particle size is less than about 1000 nm, more preferably less than about 400 nm, yet more preferably less than about 300 nm, and most preferably less than about 250 nm. It is preferred that at least about 95%, defining "d 9S " and, more preferably, at least about 99%, defining "d 99 " of particles have a median particle size of less than about 400 nm.
- the surface modifier if not present in the spray dried powder, must be added to the dispersing liquid medium in which the therapeutic or diagnostic agent is essentially insoluble to form a stable formulation.
- the concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0 to about 60%, and preferably from about 5 to about 30% (w/w).
- the concentration of the surface modifier can vary from about 0.1 to about 90%, and preferably from about 1 to about 75%, more preferably about 10 to about 60%, and most preferably about 10 to about 30% by weight of the total weight of the drug and the modifier.
- Nanocomposite host materials particularly useful in the present invention are water-soluble sugars such as sucrose, D( + )-lactose monohydrate, ⁇ -D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol; stabilizers such as polyvinyl alcohol-polyvinyl acetate copolymers; surfactants such as PluronicTM F-68, Brij ® 30, igepal CO-520 ® and TetronicTM 908.
- the amount of host materials in the nanocomposite particles can vary from about 10 to about 90%, preferably about 30 to about 90%, more preferably about 40 to about 80%, and most preferably about 50 to about 70% by weight based on the total weight of the drug and host materials.
- therapeutic agents which satisfy the matrix mediated synthesis of nanoparticles are any agents used to treat a disease or condition, such as, but not limited to analgesic and- antiinflammatory agents including aspirin, naproxen, indomethacin, ibuprofen, fenoprofen and acetaminophen; antibiotic agents including penicillins, tetracyclines, aminiglycoside antibiotics, and clindamycin; immunosuppressive agents, immunostimulatory agents, antifungal agents, antiviral agents, antineoplastic agents, anticancer agents, odor masking agents, insect repelling agents, peptides, immune reagents, anesthetic agents, antiseptic agents, antihistamine agents, antioxidants, antidiabetic agents, antiepileptic agents, muscle relaxants, stimulants, vitamins, hormones, cough suppressants, anti-
- analgesic and- antiinflammatory agents including aspirin, naproxen, indomethacin, ibuprofen,
- Such therpeutic agents can be peptides, proteins, nucleic acids of any suitable size, carbohydrates, lipids, steroids, and the like, and combinations thereof as covendedly combined or by admixture.
- Such therapeutic agents can also be tissue growth factors, liposaccharide complexing agents, and the like.
- the amount of drug in the nanocomposite particles can vary from about 10 to about 90%, preferably about 10 to about 70%, more preferably about 20 to about 60%, and most preferably about 30 to about 50% by weight based on the total weight of the drug and host materials.
- the composite approach can offer a number of advantages in terms of reducing the particle size, yield, production rate and phase distribution flexibility. Since sugars such as sucrose, D( + Hactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol, surfactants such as Pluronic F-68, and Tetronic 908, and stabilizers polyvinyl alcohol-polyvinyl acetate copolymers are highly soluble in water, but not the ethyl 3,5-diacetamido-2,4,6- triiodobenzoate and naproxen crystals, dispersing the composite particles in water with about 0.03 wt.% PluronicTM F-68 and removing the aqueous sugar solutions result in the formation of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanocrystals.
- Pluronic F-68 and Tetronic 90
- the concentration of the therapeutic or diagnostic agent in the liquid medium can vary from about 0 to about 60%, and preferably from about 5 to about 30% (w/w) .
- the concentration of the surface modifier can vary from about 0.1 to about 90%, and preferably from about 1 to about 75%, more preferably about 10 to about 60%, and most preferably about 0 to about 30% by weight of the total weight of the drug and the modifier.
- nanoparticles that are synthesized by the method of the invention, which include a therapeutic or diagnostic agent
- drug nanoparticles can be administered orally, topically, rectally, nasally, vaginally, by inhalation, for example by use of an aerosol, or parenterally, i.e. intramuscularly, subcutaneously, intraperitoneally, intraventricularly, or intravenously.
- the drug nanoparticles are administered alone, or they are combined with a pharmaceutically-acceptable carrier or excipient according to standard pharmaceutical practice.
- the drug nanoparticles are used in the form of tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like.
- carriers that are used include lactose, sodium citrate and salts of phosphoric acid.
- Various disintegrants, such as starch, and lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc are commonly used in tablets.
- useful diluents are lactose and high molecular weight polyethylene glycols.
- sterile suspensions of the drug nanoparticles are usually prepared, and the pH of the suspensions are suitably adjusted and buffered.
- the total concentration of solutes are controlled to render the preparation isotonic.
- ointments or droppable liquids are delivered by ocular delivery systems known to the art, such as applicators or eye droppers.
- Such compositions include mucomimetics, such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or polylvinyl alcohol), preservatives, such as sorbic acid, EDTA or benzylalkonium chloride, and the usual quantities of diluents and/or carriers.
- diluents and/or carriers are selected as appropriate for formation of an aerosol.
- the drug nanoparticles are administered in an effective amount.
- An effective amount is an amount effective to either ( 1 ) reduce the symptoms of the disease sought to be treated or (2) induce a pharmacological change relevant to treating or preventing or diagnosing the disease sought to be treated or prevented or diagnosed.
- FIG. 1 This example illustrates spray drying equipment as used in the context of the present invention.
- Spray drying equipment used for demonstrations of the present invention is schematically displayed in Fig. 1 .
- the spray drying equipment consists of a feed delivery system, a nebulizer, a glass drying tube of about 3 meters in length with 5-temperature zones, T, to T 5 , a filter to collect the powder, a liquid N 2 trap for the solvent, and a vacuum pump.
- This spray dryer is similar to parallel
- the 5-temperature zones, T to T 5 ranged in temperature from about
- This example illustrates one embodiment of the- present invention, whereby nanoparticles were generated using the spray drying equipment of Example 1 .
- Solutions with ethyl 3,5-diacetamido-2,4,6-triiodobenzoate manufactured by Nanosystems, Inc., Collegeville, PA
- sugar 1 :2 and 1 :9 wt. % were prepared by dissolving ethyl 3,5-diacetamido-2,4,6-triiodobenzoate and one of the following sugars; sucrose, D( + )-lactose monohydrate, ?-D-lactose, L(-)-sorbose, D( + )-glucose and D-mannitol in DMSO and water by the following procedure: In a 200 mL bottle, 5 g ethyl
- 3,5-diacetamido-2,4,6-triiodobenzoate was dissolved in 100 mL DMSO. To this solution, 10 g of one of the aforementioned sugars was dissolved in 10 mL water, and was added drop by drop, and resulted in a clear solution.
- the moistened solid was suspended in a finely divided state in a medium velocity (20 to 1 00 m - s "1 ) hot nitrogen stream.
- the resulting dried, fine particulate material i.e., the nanocomposite powder, was collected in the filter by maintaining a filter pressure draft of about 0.01 to 0.05 MPa by using the vacuum pump, as depicted in Fig. 1 .
- the residence time for a droplet in the glass tube was 2 to 10 seconds.
- the spray dried nanocomposite powders were dispersed in water with surfactant by sonication using an ultrasonic power supply having a frequency of either 20 or 80 kHz for about 1 to about 5 min. From particle size analysis, it was determined that these nanocomposite powders, when rehydrated in water with 0.1 % (w/v) PluronicTM F-68 surfactant, yielded ethyl 3,5-diacetamido-2,4,6- triiodobenzoate nanoparticle formulations with median particle diameters of 1 60 to 275 nm. Table 1 lists the ethyl
- Ethyl 3,5-diacetamido-2,4,6-triiodobenzoate:sucrose (1 :2 wt. %) nanocomposite particles were analyzed by scanning and transmission electron microscopy, SEM and TEM, respectively, and energy dispersive analysis by x-ray.
- the SEM micrographs showed agglomerates of composite particles, whereas the TEM micrographs (not shown) showed the distribution of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate particles (which are electron dense, thus darker structures) and sucrose particles (less electron dense relative to the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate, thus lighter structures) to be uniform in the nanocomposite.
- the ethyl 3,5-diacetamido-2,4,6-t ⁇ odobenzoate particle size as seen in the micrographs varied from about 1 5 nm to about 45 nm, whereas the sucrose particle size ranged from about 90 nm to about 200 nm.
- the energy dispersive analysis by x-ray demonstrated the presence of iodine atoms of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate throughout the composite particles, as can be seen in the graph of Fig. 3, wherein the x-axis is labelled as keV for x-ray energy levels and peaks are labeled to identify those associated with carbon (C), oxygen (O), iron (Fe), copper (Cu), and iodine (I) .
- 3,5-diacetamido-2,4,6-triiodobenzoate particle size a pressure atomizer was used.
- the diameter of droplets generated from the pressure atomizer was 10 to 30 ⁇ m, whereas the solution flow rate was varied between 1 .5 to 3 mL/min.
- These atomized droplets were transported through the glass tubes of the spray drying equipment with 5-temperature zones as depicted in Fig. 1 .
- the maximum temperature of the glass tube was 250°C. Evaporation of water and DMSO within the tube resulted in air-born ethyl 3,5-diacetamido-2,4,6-triiodobenzoate:sugar nanocomposite particles. These particles were collected in a finely woven Gortex bag (Grade P-80; purchased from Standard Filter Co).
- CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
- This example illustrates production of nanoparticles using the present invention.
- Solutions with 1 to 20 g ethyl 3, 5-diacetamido-2,4,6- t ⁇ iodobenzoate per 100 mL l -methyl-2-pyrrol ⁇ d ⁇ none ( 1 2 MPO) were prepared by the following procedure. In a 250 mL beaker, 5 g ethyl 3,5-diacetamido-2,4,6-triiodobenzoate and 100 mL 1 2 MPO and 1 .5 g were added, and sonicated for 1 5 minutes. Sonication accelerated the dissolution of ethyl 3,5-diacetamido-2,4,6- triiodobenzoate in 1 2 MPO.
- solutions of 5 g ethyl 3,5-diacetamido-2,4,6-triiodobenzoate per 100 mL 12 MPO with either 0.1 5 g or 1 .5 g PluronicTM F-68 were prepared as described above.
- These ethyl 3,5-diacetamido-2,4,6-triiodobenzoate solutions were spray dried using the spray drier described in Example 1 .
- the maximum drying temperature was 250°C to produce the nanoparticles.
- the as-produced fine powders were collected in a filter bag.
- Tables 3-6 list the particle sizes of ethyl 3,5-diacetamido-2,4,6- triiodobenzoate spray dried from the aforementioned ethyl 3,5-diacetamido-2,4,6-triiodobenzoate ("CMP- 1 ”) per 100 mL 1 2 MPO solutions, as well as other parameters measured.
- CMP- 1 ethyl 3,5-diacetamido-2,4,6- triiodobenzoate
- volume of solvent added was 100 mL, ' with respect to 100 L solvent; * * measured with a Malvern Zetasizer 4, "diameter (%) based on volume distribution, wherein at least about 10%, 50%, or 90%, as indicated, of the particles have the specified number average particle size.
- volume of solvent added was 100 mL, ' with respect to 100 mL solvent; measured with a Malvern Zetasizer 4, ' 'diameter on volume %.
- volume of solvent added was 100 mL; ' with respect to 100 mL solvent; * * measured with a Malvern Zetasizer 4, "diameter (%) based on volume distribution, wherein at least about 10%, 50%, or 90%, as indicated, of the particles have the specified number average particle size.
- T 5 60°C or 1 25 °C
- Example 5 This example illustrates production of the ethyl
- An ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle formulation was prepared by dispersing 4 g of the ethyl
- 3,5-diacetamido-2,4,6-triiodobenzoate ?D-Lactose ( 1 :2 wt. %) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) PluronicTM F-68 in water (pH 4.20). About 1 to 10 mg 1 -octanol was added as a defoaming agent. The nanocomposite mixture was sonicated for 5 to 10 minutes to form a stable and homogeneous ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle formulation.
- the median particle size of the dispersion measured by the laser light scattering method using Horiba LA-900 was 255 nm, and all the particles in the dispersion maintained a size of less than 400 nm.
- Example 6 This example illustrates production of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/lgepal CO-520 ® formulation 1 , which is produced in the context of the present invention.
- a ethyl 3,5-diacetamido-2,4, 6-triiodobenzoate nanoparticle formulation was prepared by dispersing 4 g of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate: ⁇ D-Lactose ( 1 :2 wt. %) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) 4- (C 9 H 19 )C 6 H 4 O(CH 2 CH 2 O) 4 CH 2 CH 2 OH (Igepal CO-520 ® ; purchased from Aldrich Chemical Co., Inc., Catalog ft 23,864-3) in water.
- Example 5 About 1 to 10 mg 1 -octanol was added as a defoaming agent. As described in Example 5, the formulation was sonicated and the particle size was measured. The median particle size of the dispersion was 205 nm and all the particles in the dispersion maintained a size of less than 400 nm.
- This example illustrates production of the ethyl - 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/lgepal CO-520 ® formulation 2, which is produced in the context of the present invention.
- a CMP-1 nanoparticle formulation was prepared by dispersing 4 g of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate:D-Mannitol ( 1 :2 wt.%) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) Igepal CO-520 ⁇ in water. About 1 to 10 mg 1 -octanol was added as a defoaming agent. As described in example 6, the formulation was sonicated and the particle size was measured. The median particle size of the dispersion was 295 nm, and all the particles in the dispersion maintained a size less than 400 nm.
- This example illustrates production of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/Brij ® 30 formulation, which is produced in the context of the present invention.
- a ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle formulation was prepared by dispersing 4 g of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate: ?-D-Lactose ( 1 :2 wt. %) nanocomposite (prepared as in Example 2) in 20 mL of 1 % (w/v) C 12 H 25 (OCH 2 CH 2 ) 4 OH (Brij ® 30; purchased from Aldrich Chemical
- This example illustrates production of the ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticle/TetronicTM 908 formulation, which is produced in the context of the present invention.
- This example illustrates certain applications of the present invention for the preparation of naproxen-co ⁇ taining nanoparticles.
- Solutions of naproxen and host matrices such as ethyl cellulose, sucrose, glucose, and D-mannitol in alcohol, water, DMF, and DMSO were spray dried using the spray dryer described in Example 1 .
- the size of the atomized droplets was about 1 -5 ⁇ m, and the maximum spray drying temperature was 1 50°C.
- Table 7 shows the naproxen nanocomposite formulations prepared by this method. The particle size was measured using a Shimadzu SALD-2001 laser diffraction particle size analyzer.
- Naproxen nanoparticle formulations were prepared by dispersing the nanocomposite powders in water saturated with naproxen and 0.1 % (W/V) Brij ® 30, at pH 2.5 and sonicating for 5 min. The temperature of these dispersions during preparation and particle size analysis were maintained below 10°C.
- naproxen nanoparticles of less than 400 nm resulted depending on the sugar selected as matrix.
- sucrose, glucose, and D-mannitol provided nanoparticles of less than 400 nm.
- An x-ray diffraction analysis using standard methods was done for the 5 g naproxen/5 g ethyl cellulose nanocomposite, which was prepared using the spray drying equipment described in Example 1 .
- This example illustrates production of naproxen nanoparticles using various matrices.
- Each of the matrices used in the above-described process to prepare nanoparticles resulted in particles of less than 400 nm.
- This example illustrates the effect of varying the concentration of the agent in a solution for the production of drug nanoparticles on the median size of the resultant particles.
- Nanoparticles that included ethyl 3,5-diacetamido-2,4,6- triiodobenzoate as the agent were prepared in accordance with the method set forth in Example 2, but wherein the weight of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate included in the solution per 1 00 mL of 1 2 MPO varied 2 g to 20 g. Median particle size was measured as noted above. The results are shown in the graph of Fig.
- This example illustrates the effect of varying the concentration of surfactant in a solution for the production of ethyl 3,5-diacetamido-2,4,6-triiodobenzoate nanoparticles on the median size of the resultant particles.
- Nanoparticles that included ethyl 3, 5-diacetamido-2,4,6- triiodobenzoate as the agent were prepared in accordance with the method set forth in Example 2, but wherein the weight of surfactant (PluronicTM F-68) included in the solution per 100 mL of 12 MPO varied from 0 g to 1 .5 g. Median particle size was measured as noted above. The results are shown in the graph of Fig. 5, wherein the y-axis is labeled Median Particle Size (nm) and the x-axis is labeled Weight of PluronicTM F-68 (g) /100 mL 1 2 MPO.
- Example 14 This example illustrates the effect of sonication of spray dried particles in the presence of surfactant to produce nanopart.cles.
- CMP-1 ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
- Spray dried powders containing 10 g or 5 g ethyl 3 5-diace,amido-2,4,6-triiodobenzoate per 100 mL 12 MPO were prepared in accordance with Example 2.
- the resulting powders were 25 analyzed by x-ray diffraction, using standard procedures. As can be seen in Fig. 7. wherein the y-axis is labeled Relative Intensity and the x-axis is labeled Degrees Two Theta, the x-ray diffraction results indicate no compositional differences between the untreated powder and the spray dried powders prepared from ethyl 3,5-diacetamido-2,4,6-triiodobenzoate in 1 2 MPO solutions.
Abstract
La présente invention se rapporte à un procédé de synthèse de nanoparticules consistant à combiner un agent et une matrice pour obtenir un mélange composite, et à sécher par pulvérisation ce mélange composite, les nanoparticules ayant une grosseur inférieure à 5000 nm. Les agents appropriés qui peuvent être formulés dans les nanoparticules, dans le contexte de la présente invention, sont des agents thérapeutiques et de diagnostic, des agents cosmétiques, colorants, photographiques, alimentaires, pesticides et autres.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96939455A EP0862420A4 (fr) | 1995-10-13 | 1996-10-11 | Synthese de nanoparticules medicamenteuses par sechage par pulverisation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US519495P | 1995-10-13 | 1995-10-13 | |
US60/005,194 | 1995-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997013503A1 WO1997013503A1 (fr) | 1997-04-17 |
WO1997013503A9 true WO1997013503A9 (fr) | 1997-07-31 |
Family
ID=21714643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/016417 WO1997013503A1 (fr) | 1995-10-13 | 1996-10-11 | Synthese de nanoparticules medicamenteuses par sechage par pulverisation |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0862420A4 (fr) |
WO (1) | WO1997013503A1 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
GB9710604D0 (en) * | 1997-05-22 | 1997-07-16 | Nycomed Imaging As | Contrast media |
US6433154B1 (en) | 1997-06-12 | 2002-08-13 | Bristol-Myers Squibb Company | Functional receptor/kinase chimera in yeast cells |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
CA2217095A1 (fr) * | 1997-10-22 | 1999-04-22 | Hydro-Quebec | Nanocomposites a interfaces activees prepares par broyage mecanique d'hydrures de magnesium et usage de ceux-ci pour le stockage d'hydrogene |
DE19920555B4 (de) * | 1999-05-05 | 2004-08-26 | Cognis Deutschland Gmbh & Co. Kg | Verwendung von nanoskaligen Metallseifen |
US8771740B2 (en) * | 1999-12-20 | 2014-07-08 | Nicholas J. Kerkhof | Process for producing nanoparticles by spray drying |
DE60020732T2 (de) | 1999-12-20 | 2006-05-11 | Kerkhof, Nicholas J., Rio Vista | Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
CN1830536A (zh) | 2000-05-16 | 2006-09-13 | 明尼苏达大学评议会 | 采用多喷嘴喷射产生大批生产量的颗粒 |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US6541030B2 (en) * | 2000-09-27 | 2003-04-01 | Verion Inc. | Instant water dissolvable encapsulate and process |
WO2002082900A1 (fr) | 2001-03-30 | 2002-10-24 | Rhodia Inc. | Suspension aqueuse de nanoparticules comprenant un ingredient agrochimique actif |
KR100463167B1 (ko) * | 2001-04-13 | 2004-12-23 | 주식회사 태평양 | 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물 |
US7247338B2 (en) | 2001-05-16 | 2007-07-24 | Regents Of The University Of Minnesota | Coating medical devices |
WO2003032959A1 (fr) * | 2001-10-15 | 2003-04-24 | Bosch William H | Compositions nanoparticulaires comprenant des noyaux inorganiques |
ATE401058T1 (de) | 2001-11-01 | 2008-08-15 | Nektar Therapeutics | Sprühtrocknungsverfahren |
ES2364636T3 (es) | 2001-12-19 | 2011-09-08 | Novartis Ag | Administración pulmonar de aminoglucósidos. |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
DE60329188D1 (de) | 2002-08-12 | 2009-10-22 | Bend Res Inc | Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren |
GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0310300D0 (en) * | 2003-05-06 | 2003-06-11 | Univ Belfast | Nanocomposite drug delivery composition |
EP1635786A2 (fr) | 2003-05-28 | 2006-03-22 | Nektar Therapeutics | Sechage par pulverisation d'une solution aqueuse alcoolique pour la fabrication d'une microparticule contenant un principe actif insoluble dans l'eau et ayant un enrobage partiel ou complet comprenant un acide amine ou un phospholipide |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
DE10351004A1 (de) | 2003-10-30 | 2005-05-25 | Basf Ag | Nanopartikuläre Wirkstoffformulierungen |
WO2006083326A2 (fr) | 2004-08-07 | 2006-08-10 | Cabot Corporation | Fabrication d'une dispersion gazeuse de nanoparticules, et produits contenant des nanoparticules et traitement de ceux-ci |
US7829000B2 (en) | 2005-02-25 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Core-shell solid freeform fabrication |
EP1868578A2 (fr) * | 2005-03-23 | 2007-12-26 | Elan Pharma International Limited | Formulations d'un corticosteroide nanoparticulaire et d'un antihistamine |
CN101277682B (zh) | 2005-07-28 | 2015-07-29 | Isp投资有限公司 | 无定形依发韦仑及其生产 |
FR2891275B1 (fr) * | 2005-09-26 | 2007-11-16 | Commissariat Energie Atomique | Procede de fabrication de compositions comprenant des nanoparticules d'un elememnt ou compose chimique dispersees dans une matrice organique |
US9108217B2 (en) | 2006-01-31 | 2015-08-18 | Nanocopoeia, Inc. | Nanoparticle coating of surfaces |
US7951428B2 (en) | 2006-01-31 | 2011-05-31 | Regents Of The University Of Minnesota | Electrospray coating of objects |
US9248217B2 (en) | 2006-01-31 | 2016-02-02 | Nanocopocia, LLC | Nanoparticle coating of surfaces |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
WO2008034273A1 (fr) | 2006-09-22 | 2008-03-27 | Mivital Ag | Émulsions contenant de la gomme arabique |
US9040816B2 (en) | 2006-12-08 | 2015-05-26 | Nanocopoeia, Inc. | Methods and apparatus for forming photovoltaic cells using electrospray |
WO2008080037A2 (fr) | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Caroténoïdes à biodisponibilité améliorée |
EP2125938A2 (fr) | 2007-01-26 | 2009-12-02 | Isp Investments Inc. | Procédé de traitement de formulation pour produire des produits séchés pour une pulvérisation |
WO2008135855A2 (fr) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticules contenant un inhibiteur de la protéine de transfert d'ester de cholestéryle et un polymère non ionisable |
WO2008135828A2 (fr) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticules comprenant un médicament, de l'éthylcellulose et un sel biliaire |
WO2008149230A2 (fr) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate |
EP2162120B1 (fr) | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticules comportant un polymère cellulosique non ionisable et un copolymère bloc amphiphile non ionisable |
WO2009073215A1 (fr) | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension |
WO2009073216A1 (fr) | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine |
EP2378869A2 (fr) * | 2008-12-18 | 2011-10-26 | Basf Se | Dispersion aqueuse contenant des particules de pesticides et un saccharide en solution |
JP2013503166A (ja) * | 2009-08-25 | 2013-01-31 | カーディオカイン・バイオファーマ・エルエルシー | 不溶性剤を送達するための組成物 |
WO2013132457A2 (fr) | 2012-03-07 | 2013-09-12 | National Institute Of Pharmaceutical Education And Research (Niper) | Compositions de dispersions de solides nanocristallins et leur procédé de préparation |
RU2561686C1 (ru) * | 2014-04-01 | 2015-08-27 | Александр Александрович Кролевец | Способ инкапсуляции аспирина в ксантановой камеди |
EP3586827A1 (fr) | 2018-06-29 | 2020-01-01 | Consejo Superior de Investigaciones Cientificas (CSIC) | Formulation pharmaceutique présentant une solubilité et une biodisponibilité améliorées |
CN114886856A (zh) * | 2022-06-09 | 2022-08-12 | 山西辅仁恒峰药业有限公司 | 一种奥司他韦纳米干混悬剂的制备方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
ES2127835T3 (es) * | 1992-10-26 | 1999-05-01 | Sanol Arznei Schwarz Gmbh | Procedimiento para la preparacion de microcapsulas. |
-
1996
- 1996-10-11 EP EP96939455A patent/EP0862420A4/fr not_active Withdrawn
- 1996-10-11 WO PCT/US1996/016417 patent/WO1997013503A1/fr not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997013503A9 (fr) | Synthese de nanoparticules medicamenteuses par sechage par pulverisation | |
WO1997013503A1 (fr) | Synthese de nanoparticules medicamenteuses par sechage par pulverisation | |
JP6025706B2 (ja) | 微小粒子またはナノ粒子を生成する方法および装置 | |
Plakkot et al. | Comminution of ibuprofen to produce nano-particles for rapid dissolution | |
Caliceti et al. | Effective protein release from PEG/PLA nano-particles produced by compressed gas anti-solvent precipitation techniques | |
RU2186562C2 (ru) | Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления | |
US5718919A (en) | Nanoparticles containing the R(-)enantiomer of ibuprofen | |
FI108333B (fi) | Menetelmõ nanopartikkelikoostumusten valmistamiseksi | |
Kaialy et al. | Recent advances in the engineering of nanosized active pharmaceutical ingredients: promises and challenges | |
US6756062B2 (en) | Preparation of drug particles using evaporation precipitation into aqueous solutions | |
CA2458889C (fr) | Procede de precipitation de particules medicamenteuses | |
Yadav et al. | Nanosuspension: A promising drug delivery system | |
US20050139144A1 (en) | Method for the production and the use of microparticles and nanoparticles by constructive micronisation | |
US20120231093A1 (en) | Method for preparing nano-scale or amorphous particle using solid fat as a solvent | |
Li et al. | Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation | |
Zhang et al. | Nanosuspensions of poorly water soluble drugs prepared by top-down technologies | |
Dan et al. | Microcrystalline cellulose-carboxymethyl cellulose sodium as an effective dispersant for drug nanocrystals: A case study | |
Matos et al. | Single-step coprecipitation and coating to prepare curcumin formulations by supercritical fluid technology | |
Pu et al. | Ultrafine clarithromycin nanoparticles via anti-solvent precipitation in subcritical water: Effect of operating parameters | |
JP2007503399A (ja) | 生物活性化合物の粒子サイズの低減 | |
Vatanara | Spray drying of nanoparticles to form fast dissolving glipizide | |
Sheng et al. | Continuous and scalable process for the production of hollow crystals of a poorly water-soluble active pharmaceutical ingredient for dissolution enhancement and inhaled delivery | |
Wang et al. | A novel strategy to produce highly stable and transparent aqueous ‘nanosolutions’ ofwater-insoluble drug molecules | |
Raula et al. | Aerosol flow reactor method for the synthesis of multicomponent drug nano-and microparticles | |
Jaspreet et al. | Development of Nanocrystal Formulation with Improved Dissolution. J |